by Jakub Jarolím, Business Intelligence Department
Vážený uživateli, je nám líto, ale Váš prohlížeč nepodporuje plné zobrazení webu. Doporučujeme Vám přejít na jeho aktuálnější verzi (MS Edge) nebo na některý z nejčastějších prohlížečů (Chrome, Firefox, Safari).
SOTIO Biotech
15/8/2025
June 2025 Biotechnology: Review of news from the most innovative therapeutic areas and the business development transactions
Market
President Trump wants interest rate cut to 1% and would “love” if Fed’s Powell resigned
US stocks took a breather end of June as the tenuous Israel-Iran cease fire continued to hold. Fed Chair Jerome Powell said inflation in goods prices is expected to go up due to Trump's tariffs. Trump said he wants interest rate cut to 1% and that he would “love” if Powell resigned.
Antibody-Drug Conjugates
FDA approved Datroway for patients with pre-treated advanced EGFR-mutated NSCLC
Detail článkuInterleukin-15 and Interleukin-2
Rezpegaldesleukin meets primary and key secondary endpoints in REZOLVE-AD Phase 2
Nektar announced statistically significant data from the 16-week induction period of the ongoing Phase 2b REZOLVE-AD study of investigational rezpegaldesleukin, an IL-pathway agonist and regulatory T-cell (Treg) proliferator.
Cell Therapies
JNJ's dual-targeting CAR-T shows first encouraging results in large B-cell lymphoma
BMS announced that FDA approved label updates for both of its CAR T cell therapies, Breyanzi (liso-cel) for the treatment of large B cell lymphoma (LBCL) and other lymphomas and Abecma (ide-cel) for the treatment of multiple myeloma. These label updates reduce certain patient monitoring requirements and remove the Risk Evaluation and Mitigation Strategy (REMS) programs that had been in place since each product was initially approved.
Sdílet na sociálních sítích